Take­da antes up $44M for rare dis­ease pact, turn­ing to Ox­ford spin­out's ex­o­some tech

More than two weeks in­to Take­da’s new work guide­lines in re­sponse to the Covid-19 cri­sis — or­der­ing staffers to work from home and stay off the road — the BD team has some­thing to cel­e­brate.

In a boost to the rare dis­ease unit built around Shire’s lega­cy R&D op­er­a­tion af­ter its $62 bil­lion buy­out deal, Take­da has inked a new col­lab­o­ra­tion in pur­suit of ex­o­some de­liv­ery tech­nol­o­gy. Their part­ner of choice is Evox Ther­a­peu­tics, an Ox­ford spin­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.